LETTER TO THE EDITOR

Live SARS-CoV-2 is difficult to detect in patient aerosols

1 | DEAR EDITOR COWLING

As the COVID-19 pandemic rages, there has been much debate regarding the importance of bioaerosols in SARS-CoV-2 transmission. Circumstantial evidence indicates that aerosol transmission is a likely contributor to the current pandemic,¹⁻³ yet research teams have had difficulty isolating live virus when using traditional aerosol sampling techniques.⁴⁻⁶ To our knowledge, thus far only two research teams have successfully cultured airborne SARS-CoV-2 outside of laboratory simulations,⁷ with one team finding evidence of viral replication in the absence of cytopathic effect.⁸⁻⁹ Despite the demonstrated challenges in capturing suspended live virus, respiratory transmission is now thought of as the primary mode of SARS-CoV-2 infection. By contrast, SARS-CoV-2 has been readily cultured from nasopharyngeal (NP) swabs, saliva, blood, stool, and semen.⁴⁻¹² Mounting evidence indicates that COVID-19 patients are most infectious within the first eight days following symptom onset,⁴⁻¹³ with some outliers shedding live virus for up to 18 days.¹⁴ Increased viral load is associated with better odds of culturing virus, with cut-off values reported at 24 and 34 RT-PCR cycle thresholds.¹⁻³

Building on previous work carried out by our team,¹⁵ we sought to enroll home isolated SARS-CoV-2 positive patients early in their disease progression to estimate the viability of the virus in biological, environmental, and bioaerosol samples and assess aerosol transmission of SARS-CoV-2.

From October 2020 to January 2021, we visited eight patients in their homes in and around Durham, North Carolina soon after they were confirmed by molecular assay to be infected with SARS-CoV-2. After informed consent was obtained, we asked patients to complete a brief questionnaire, and to permit the collection of a NP swab, passive saliva sample, fomite swabs, and bioaerosol samples. Patients were also asked to self-collect a rectal swab sample. All study procedures were approved by the Duke University Institutional Review Board (Pro00105055).

Bioaerosol sampling was carried out using National Institute for Occupational Safety and Health (NIOSH) BC 251 aerosol samplers, placed ~1.5 meters off the ground at distances of ~1 meter, 1.4 meters, 2.2 meters, and 3.2 meters from the participant’s head. The participants were asked to remain stationary in their room and the samplers were run for approximately two hours at a calibrated flow-rate of 3.5 L/min.¹⁵ SKC 20-ml BioSamplers (SKC, Inc., Pennsylvania, USA), prepared with 16 mL phosphate-buffered saline (PBS) and 0.5% bovine serum albumen (BSA), were placed beneath the NIOSH samplers on one side of the room and run simultaneously at the recommended flow rate of 12.5 L/min. These samplers are designed to capture viral matter in liquid media to enhance viability. It is important to note that we have previously used both types of samplers to capture live influenza A virus.¹⁶⁻¹⁹ Biological samples and fomite swabs were collected and processed as previously described,¹⁵ using FLOQSwab® (Copan, Murrieta, California) or sterile BD™ swabs (BD Diagnostics, Sparks, Maryland) and 1.5 mL VTM (Redoxica, Little Rock, Arkansas). Cell phones, TV remote controls, and door knobs were preferentially sampled, along with up to three other high-touch surfaces, as indicated by the participant.

Viral RNA was extracted from processed samples using QIAamp Viral RNA Mini Kits (QIAGEN, Hilden, Germany), with the resultant product used in an adapted Center for Disease Control and Prevention (CDC) 2019-nCoV real-time RT-PCR assay.¹⁵ Specimens with molecular evidence of SARS-CoV-2 infection were inoculated onto VeroE6/TMPRSS2 cells²⁰ using 250 µL of sample for 7 days. Cells were monitored for cytopathic effect (CPE) every 48 hours. Cells and supernatant were harvested 7 days post-inoculation. RNA extracts were then screened for SARS-CoV-2 with the real-time RT-PCR assay and considered positive when the CT value was at least 2 points below the original result and CPE was present.¹⁵

All participants presented with mild to moderate illness. The majority of the participants were females (n = 7, 87.5%). The predominantly represented race was white (n = 5, 62.5%), with two Black participants (25.0%), and one Asian (12.5%). One participant identified as Hispanic, and a second as Indian. The mean age was 41.4 years, with a range of 29 to 53 years. Among all participants, five lived in a private house, one in an apartment complex, and two in a residential shelter.

Participants were typically enrolled within three days of symptom onset (one patient was enrolled on day 8), and reported experiencing between zero and seven common COVID-19 symptoms at time of enrollment, with cough, fatigue, and body ache the most frequently listed (Table S1). Chronic health conditions were reported by five participants, including hypertension, diabetes, and hypothyroidism. Three participants reported having traveled

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2021 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
**TABLE 1**  Cycle threshold values for all samples with molecular evidence of SARS-CoV-2 nucleic acid, through the CDC 2019-nCoV RT-PCR assay. Samples with molecular evidence of SARS-CoV-2 were cultured in TMPRSS2 cells and considered positive upon observation of cytopathic effect followed by confirmatory RT-PCR. Two forms of aerosol sampling (NIOSH BC 251 Cyclone Sampler and SKC 20 ml BioSampler) were simultaneously employed at varying distances from the participant’s head.

| Patient | Sample Type a | N1 (Ct) b | N2 (Ct) b | Culture Results c | Fomites | Ct Range for N1 and N2 b | Culture Results c | Aerosol Samples | Ct Range for N1 and N2 b | Culture Results c |
|---------|----------------|-----------|-----------|-------------------|---------|------------------------|-------------------|-----------------|------------------------|-------------------|
| 1       | Saliva         | 29.0      | 37.1      | N                 | --      | --                     | --                | --              | --                     | --                |
| 2       | Saliva         | 38.2      | 39.0      | N                 | --      | --                     | --                | --              | --                     | --                |
| 3       | NP Swab        | 16.9      | 17.3      | P                 | Cell phone, sink handle (bathroom) | 29.0 - 39.0 | N | 1 m - SKC; 1.4 m - NIOSH | 36.1 - 38.6 | N |
|         | Saliva         | 29.1      | 33.7      | P                 | --      | --                     | --                | --              | --                     | --                |
|         | Rectal Swab    | 35.0      | 34.6      | N                 | --      | --                     | --                | --              | --                     | --                |
| 4       | NP Swab        | 17.3      | 18.7      | P                 | Cell phone, TV remote, bathroom door knob | 33.4 - 39.4 | N | 1.4 m - SKC; 2.2 m - SKC | 36.4 - 39.8 | N |
|         | Saliva         | 18.2      | 19.3      | P                 | --      | --                     | --                | --              | --                     | --                |
|         | Rectal Swab    | 35.3      | 37.5      | N                 | --      | --                     | --                | --              | --                     | --                |
| 5       | NP Swab        | 17.9      | 18.6      | P                 | Cell phone | 37.8 - 38.7 | N | 1.4 m - NIOSH | 36.9 | N |
|         | Saliva         | 29.5      | 31.6      | P                 | --      | --                     | --                | --              | --                     | --                |
|         | Rectal Swab    | 34.1      | 37.0      | N                 | --      | --                     | --                | --              | --                     | --                |
| 6       | NP Swab        | 15.0      | 15.9      | P                 | Cell phone, bathroom door knob, computer | 36.7 - 39.6 | N | 1 m - NIOSH; 1.4 m - NIOSH, SKC; 2.2 m - NIOSH, SKC | 31.8 - 39.9 | N |
|         | Saliva         | 24.4      | 27.3      | P                 | --      | --                     | --                | --              | --                     | --                |
|         | Rectal Swab    | 31.3      | 33.5      | N                 | --      | --                     | --                | --              | --                     | --                |
| 7       | NP Swab        | 18.1      | 18.6      | P                 | Toilet handle | 36.7 - 38.6 | N | -- | -- | -- |
|         | Saliva         | 24.7      | 25.5      | P                 | --      | --                     | --                | --              | --                     | --                |
|         | Rectal Swab    | 29.6      | 31.2      | P                 | --      | --                     | --                | --              | --                     | --                |
| 8       | NP Swab        | 25.6      | 26.7      | P                 | TV remote, computer (mouse) | 27.0 - 39.3 | N | -- | -- | -- |
|         | Saliva         | 31.2      | 32.4      | N                 | --      | --                     | --                | --              | --                     | --                |
|         | Rectal Swab    | 39.8      | 39.7      | N                 | --      | --                     | --                | --              | --                     | --                |

aNP=nasopharyngeal;  
bCt=cycle threshold;  
cP=positive and N=negative = the patient’s spouse (also SARS-CoV-2 positive) was present during sampling.
either domestically or internationally in the month prior to study enrollment. Sampling sites in participants' homes varied in size, with some permitting as few as 6 total bioaerosol samplers and others as many as 10 samplers. Among the eight participants, a total of 139 samples were collected. Among those, 45 (32.4%) were SARS-CoV-2 positive by RT-PCR, including 20 biological samples (83.3% of 24 total), 12 fomites (25.0% of 48 total), and 13 bioaerosol samplers (19.0% of 42 NIOSH Samplers, 20.0% of 25 SKC Samplers) (Table 1). Viable virus was recovered from six NP swabs (75.0%), five saliva samples (62.5%), and one rectal swab (12.5%). Despite this indicator of live viral shedding, none of the RT-PCR positive fomite or bioaerosol samples had evidence of culturable SARS-CoV-2.

Findings presented here may not be representative of the general population, as recruitment was influenced by patient willingness to allow researchers into their homes and logistical constraints required households to be within close proximity of Duke University. Additionally, considerable variation between individual home floor plans affected the set-up of aerosol samplers in participants' living quarters.

Despite these limitations, this study importantly adds to the body of work demonstrating SARS-CoV-2 viability in varying biological samples gathered early in the disease progression of mild to moderate COVID-19 illness, and affirms that fomites are unlikely to be a primary source of viral transmission. As compared to our previous efforts to capture live SARS-CoV-2 in bioaerosols, the use of VeroE6/TMPRSS2 cells (which are more sensitive in culturing SARS-CoV-2) and the inclusion of the SKC BioSampler wet sampling technique (also thought to increase live virus detections) did not improve study findings. Our inability to detect viable virus in the air might be explained by insensitive sampling techniques or the notion that the participants had ceased shedding virus in aerosol by the time we engaged them.

ETHICS APPROVAL
All study procedures were approved by the Duke University Institutional Review Board (Pro00105055).

ACKNOWLEDGEMENTS
We thank Andrew Pekosz, PhD, Professor and Vice Chair of the W. Harry Feinstone Department of Molecular Microbiology & Immunology at Johns Hopkins University for his virological advice. We thank Dr Makoto Takeda, MD, PhD, Director, Department of Virology 3 of the National Institute of Infectious Diseases in Japan for permitting us to use the VeroE6/TMPRSS2 cells. We thank Jamie Roberts, Dr Elizabeth Petzold, and the Duke COVID Outpatient Recruitment team for identifying and screening eligible patients, as well as each of the study participants who shared their stories and allowed us to come into their homes to sample.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTION
Emily R. Robie: Data curation (lead); Investigation (equal); Project administration (supporting); Writing-original draft (lead); Writing-review & editing (equal). Anfal Abdelgadir: Investigation (equal); Writing-review & editing (equal). Raquel A. Binder: Investigation (equal); Supervision (supporting); Writing-review & editing (equal). Gregory C. Gray: Conceptualization (lead); Funding acquisition (lead); Investigation (equal); Methodology (lead); Project administration (lead); Resources (lead); Supervision (lead); Writing-review & editing (equal).

Funding information
This study was supported by Professor Gray's discretionary funding and grants from Duke University's Clinical Translational Science Institute and Duke Medicine and Engineering (MEDx).

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1111/irv.12860.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Emily R. Robie1,2
Anfal Abdelgadir1,2
Raquel A. Binder1,2
Gregory C. Gray1,2,3,4

1Division of Infectious Diseases, School of Medicine, Duke University, Durham, NC, USA
2Duke Global Health Institute, Duke University, Durham, NC, USA
3Global Health Research Center, Duke Kunshan University, Kunshan, China
4Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore

Correspondence
Gregory C. Gray, Division of Infectious Diseases, School of Medicine, Duke University, Durham, NC 27710, USA.
Email: gregory.gray@duke.edu

ORCID
Gregory C. Gray https://orcid.org/0000-0002-4628-5908

REFERENCES
1. Miller SL, Nazaroff WW, Jimenez JL, et al., Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the skagit valley choral superspreading event. Indoor Air. 2021;31(2):314-323. http://dx.doi.org/10.1111/ina.12751
2. Lu J, Gu J, Li K, et al., COVID-19 outbreak associated with air conditioning in restaurant, guangzhou, china, 2020. Emerging Infectious
LETTER TO THE EDITOR

Diseases. 2020;26(7):1628-1631. http://dx.doi.org/10.3201/eid2607.2000764
3. James A, Eagle L, Phillips C. et al., High COVID-19 attack rate among attendees at events at a church — Arkansas, March 2020. MMWR. Morbidity and Mortality Weekly Report. 2020;69(20):632-635. http://dx.doi.org/10.15585/mmwr.mm6920e2
4. Meyerowitz EA, Richterman A, Gandhi RT. et al., Transmission of SARS-CoV-2: A review of viral, host, and environmental factors. Annals of Internal Medicine. 2021;174(1):69-79. http://dx.doi.org/10.7326/m20-5008
5. SWX, Ong SWX, Tan YK. et al., Lack of viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among PCR-positive air samples from hospital rooms and community isolation facilities. Infection Control & Hospital Epidemiology. 2021;1-6. http://dx.doi.org/10.1017/ice.2021.8
6. Lednicky JA, Shankar SN, Elbadry MA. et al., Collection of SARS-CoV-2 virus from the air of a clinic within a university student health care center and analyses of the viral genomic sequence. Aerosol and Air Quality Research. 2020;20(6):1167-1171. http://dx.doi.org/10.4209/aaqr.2020.02.0202
7. Lednicky JA, Lauzardo M, Fan ZH. et al., Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. International Journal of Infectious Diseases. 2020;100:476-482. http://dx.doi.org/10.1016/j.ijid.2020.09.025
8. Santarpia JL, Herrera VL, Rivera DN. et al., The Infectious Nature of Patient-Generated SARS-CoV-2 Aerosol. 2020. http://dx.doi.org/10.1101/2020.07.13.20041632
9. Santarpia JL, Rivera DN, Herrera VL. et al., Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Scientific Reports. 2020;10(1). http://dx.doi.org/10.1038/s41598-020-69286-3
10. Medeiros da Silva RC, Nogueira Marinho LC, de Araújo Silva DN. et al., Saliva as a possible tool for the SARS-CoV-2 detection: A review. Travel Medicine and Infectious Disease. 2020;38:101920. http://dx.doi.org/10.1016/j.tmaid.2020.101920
11. Zhang Y, Chen X, Song Y. et al., Excretion of SARS-CoV-2 through faecal specimens. Emerging Microbes & Infections. 2020;9(1):2501-2508. http://dx.doi.org/10.1080/22221751.2020.1844551
12. Cevik M, Tate M, Lloyd O. et al., SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and Infectiousness: a systematic review and meta-analysis. The Lancet Microbe. 2021;2(1):e13-e22. http://dx.doi.org/10.1016/s2666-5247(20)30172-5
13. Tirupathi R, Ramparas TR, Wadhwa G. et al., Viral dynamics in the upper respiratory tract (URT) of SARS-CoV-2. Infez Med. 2020;28(4):486-499.
14. Ladhani SN, Chow JY, Janarthanan R. et al., Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020. EClinicalMedicine. 2020;26:100533. http://dx.doi.org/10.1016/j.eclinm.2020.100533
15. Binder RA, Alarja NA, Robie ER. et al., Environmental and aerosolized severe acute respiratory syndrome coronavirus 2 among hospitalized coronavirus disease 2019 patients. The Journal of Infectious Diseases. 2020;222(11):1798-1806. http://dx.doi.org/10.1093/infdis/jiaa575
16. Wang X, Bailey ES, Qi X. et al., Bioaerosol sampling at a live animal market in kunshan, china: A noninvasive approach for detecting emergent viruses. Open Forum Infectious Diseases. 2020;7(5).http://dx.doi.org/10.1093/ofid/ofaa134
17. Bui VN, Nguyen TT, Nguyen-Viet H. et al., Bioaerosol sampling to detect avian influenza virus in hanoi’s largest live poultry market. Clinical Infectious Diseases. 2019;68(6):972-975. http://dx.doi.org/10.1093/cid/ciy583
18. Anderson BD, Lednicky JA, Torremorell M. et al., The use of bioaerosol sampling for airborne virus surveillance in swine production facilities: A mini review. Frontiers in Veterinary Science. 2017;4. http://dx.doi.org/10.3389/fvets.2017.00121
19. Wu Y, Shi W, Lin J. et al., Aerosolized avian influenza A (H5N6) virus isolated from a live poultry market, China. Journal of Infection. 2017;74(1):89-91. http://dx.doi.org/10.1016/j.jinf.2016.08.002
20. Matsuyama S, Nao N, Shirato K. et al., Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proceedings of the National Academy of Sciences. 2020;117(13):7001-7003. http://dx.doi.org/10.1073/pnas.2002589117

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Robie ER, Abdelgadir A, Binder RA, Gray GC. Live SARS-CoV-2 is difficult to detect in patient aerosols. Influenza Other Respi Viruses. 2021;15:554-557. https://doi.org/10.1111/irv.12860